President Trump has finalized an agreement with Merck KGaA to reduce the cost of its in vitro fertilization (IVF) drugs in the U.S., including its key therapy Gonal-F, in exchange for exemptions from threatened tariffs. Under the terms, Merck will distribute its fertility medicines through Trump’s direct-to-consumer platform, TrumpRX, expand U.S. manufacturing, and receive a priority review voucher for its Pergoveris drug. This initiative aims to make IVF more affordable, potentially cutting over $2,000 from treatment cycle costs, and is supported by White House plans to broaden employer-provided fertility coverage as an excepted benefit.
President Trump has secured an agreement with Germany's Merck KGaA to reduce the cost of IVF drugs in the U.S., including its key therapy Gonal-F, in exchange for tariff exemptions. This initiative aims to make IVF more affordable, potentially cutting over $2,000 from treatment cycles that can exceed $15,000. Merck will distribute its fertility medicines through the TrumpRX platform and expand U.S. manufacturing. For Merck KGaA, the deal provides significant strategic advantages, including relief from threatened tariffs and a priority review voucher for its Pergoveris fertility drug, already approved in 74 countries. The direct-to-consumer channel via TrumpRX could streamline distribution and potentially increase market penetration for its IVF portfolio. This move also aligns with a broader political push for domestic manufacturing. The White House's concurrent plan to allow employers to offer fertility coverage as an "excepted benefit" could further stimulate demand for IVF treatments and associated pharmaceuticals. This regulatory tailwind, coupled with the direct pricing agreement, suggests a concerted effort to expand access and affordability in the reproductive medicine sector.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
